SNDX
NASDAQSyndax Pharmaceuticals Inc.
Price$17.31-4.35 (-20.06%)
2026-03-042026-06-05
News · 26 weeks47+25%
2025-12-142026-06-07
Mix2090d
- Other10(50%)
- SEC Filings6(30%)
- Earnings2(10%)
- Insider2(10%)
Latest news
25 items- PRSyndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)NEW YORK, June 04, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (NASDAQ:SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that on June 1, 2026, the Company granted inducement awards to purchase up to 66,700 shares of common stock to four new employees under the Company's 2023 Inducement Plan. The stock options will vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of the vesting commencement date and 1/48th of the underlying shares vesting monthly thereafter over 36 months, subject to the employee's continued service relationship with Syndax through the applicable vesting dates. About Syn
- SECSEC Form DEFA14A filed by Syndax Pharmaceuticals Inc.DEFA14A - Syndax Pharmaceuticals Inc (0001395937) (Filer)
- SECSyndax Pharmaceuticals Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement8-K - Syndax Pharmaceuticals Inc (0001395937) (Filer)
- PRSyndax Announces Private Placement of $250.0 Million of Convertible Senior NotesNEW YORK, June 04, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals, Inc. ("Syndax") (NASDAQ:SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, has entered into privately negotiated subscription agreements for the issuance of $250.0 million aggregate principal amount of 2.25% Convertible Senior Notes due 2031 (the "Notes"). The sale of the Notes is expected to close on June 10, 2026, subject to customary closing conditions. J. Wood Capital Advisors LLC is acting as sole placement agent in connection with the private placement of the Notes (the "private placement"). Syndax estimates that the net proceeds from the private placement will be approximatel
- INSIDERChief Financial Officer Goldan Keith A. sold $22,351 worth of shares (1,177 units at $18.99), decreasing direct ownership by 0.84% to 139,252 units (SEC Form 4) (for withholding tax)4 - Syndax Pharmaceuticals Inc (0001395937) (Issuer)
- INSIDERChief Executive Officer Metzger Michael A sold $130,025 worth of shares (6,847 units at $18.99), decreasing direct ownership by 1% to 484,843 units (SEC Form 4) (withholding tax)4 - Syndax Pharmaceuticals Inc (0001395937) (Issuer)
- PRSyndax Highlights Revuforj® (revumenib) Data Presented at ASCO 2026, Including an Oral Presentation of Post-Transplant Data– Pooled analysis of 24 adults and children with KMT2Ar, NPM1m, or NUP98r acute leukemia who resumed revumenib post-transplant shows favorable outcomes, including a2-year overall survival rate of 90% vs historical benchmark of 51% – – Company also presented data highlighting unique aspects of revumenib's PK profile, including the ability to administer it with gastric acid reducing agents without the risk of reduced efficacy – NEW YORK, June 02, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (NASDAQ:SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today highlighted key Revuforj® (revumenib) data that was presented at the American Society
- PRSyndax to Host R&D Day Highlighting its Late-Stage Programs and Early-Stage Assets on July 14, 2026NEW YORK, June 01, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (NASDAQ:SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that it will host an R&D Day on Tuesday, July 14, 2026, at 8:30 AM ET in New York City. The R&D Day will feature presentations by Syndax's management team and key opinion leaders. The Company will highlight its late-stage revumenib and axatilimab programs, including its ongoing trials in idiopathic pulmonary fibrosis, newly diagnosed chronic graft-versus-host disease, and newly diagnosed acute leukemia. Further, the Company will detail its new early-stage assets and broader plans to leverage its capabilities a
- PRSyndax Announces Four Revuforj® (revumenib) Abstracts Accepted for ASCO 2026, Including an Oral Presentation of Post-Transplant Data– Oral presentation will highlight favorable outcomes observed among 21 adults and children with KMT2Ar, NPM1m, or NUP98r acute leukemia who received revumenib post-transplant – – Data underscoring unique aspects of revumenib's PK profile, including the ability to administer it with gastric acid reducing agents and low-fat meals, will be presented – – Design of ongoing pivotal trials of revumenib plus low or high-intensity chemotherapy in newly diagnosed NPM1m or KMT2Ar acute leukemia will be highlighted – NEW YORK, May 21, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (NASDAQ:SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced t
- PRSyndax Announces Participation in Upcoming Investor ConferencesNEW YORK, May 20, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (NASDAQ:SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that Michael A. Metzger, Chief Executive Officer, as well as members of the Syndax management team, will participate in the following upcoming investor conferences: TD Cowen 7th Annual Oncology Innovation Summit with a virtual fireside chat on Wednesday, May 27, 2026, at 1:00 p.m. ET.Jefferies Global Healthcare Conference in New York, NY with a fireside chat on Thursday, June 4, 2026, at 9:20 a.m. ET.Goldman Sachs 47th Annual Global Healthcare Conference in Miami Beach, FL, with a fireside chat on Monday, June
- PRSyndax Highlights 12 Revuforj® (revumenib) Abstracts Accepted for EHA 2026, Advancing Leadership in Menin Inhibition– Abstracts highlight strong revumenib activity across the acute leukemia treatment continuum and multiple genetic subtypes – – New real-world data show compelling outcomes and favorable tolerability with revumenib monotherapy and combination use – – Two abstracts highlight encouraging results with revumenib in the post-transplant setting – – Frontline and R/R revumenib combination data show deep responses, robust transplant rates, and favorable tolerability – – Encouraging activity observed with revumenib in R/R NUP98r acute leukemia – NEW YORK, May 12, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (NASDAQ:SNDX), a commercial-stage biopharmaceutical company advancing innovative can
- PRSyndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)NEW YORK, May 06, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (NASDAQ:SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that on May 1, 2026, the Company granted inducement awards to purchase up to 162,100 shares of common stock to eight new employees under the Company's 2023 Inducement Plan. The stock options will vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of the vesting commencement date and 1/48th of the underlying shares vesting monthly thereafter over 36 months, subject to the employee's continued service relationship with Syndax through the applicable vesting dates. About Syn
- SECSEC Form DEFA14A filed by Syndax Pharmaceuticals Inc.DEFA14A - Syndax Pharmaceuticals Inc (0001395937) (Filer)
- SECSEC Form DEF 14A filed by Syndax Pharmaceuticals Inc.DEF 14A - Syndax Pharmaceuticals Inc (0001395937) (Filer)
- SECSEC Form 10-Q filed by Syndax Pharmaceuticals Inc.10-Q - Syndax Pharmaceuticals Inc (0001395937) (Filer)
- SECSyndax Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Syndax Pharmaceuticals Inc (0001395937) (Filer)
- PRSyndax Reports First Quarter 2026 Financial Results and Provides Business Update– Total revenue of $64.9 million in 1Q26, a 224% year-over-year increase – – Revuforj® (revumenib) net revenue of $48.9 million in 1Q26, highlighting leadership in menin inhibition and increasing uptake in R/R NPM1m AML – – Niktimvo™ (axatilimab-csfr) net revenue of $55.1 million in 1Q26, resulting in Syndax collaboration revenue of $15.9 million – – New revumenib real-world, frontline, and post-HSCT maintenance data anticipated in 2Q26 – – Topline data expected in 4Q26 from Phase 2 trials of axatilimab in IPF and newly diagnosed chronic GVHD – – Company to host a conference call today at 4:30 p.m. ET – NEW YORK, April 30, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (NASDAQ:SNDX
- PRSyndax to Announce First Quarter 2026 Financial Results and Host Conference Call and Webcast on April 30, 2026NEW YORK, April 24, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (NASDAQ:SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that it will report its first quarter 2026 financial results and provide a business update on Thursday, April 30, 2026. In connection with the earnings release, Syndax's management will host a conference call and live audio webcast at 4:30 p.m. ET on Thursday, April 30, 2026. The live audio webcast and accompanying slides may be accessed through the Events & Presentations page in the Investors section of the Company's website. Alternatively, the conference call may be accessed through the following: Confere
- PRSyndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)NEW YORK, April 03, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (NASDAQ:SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that on April 1, 2026, the Company granted inducement awards to purchase up to 228,500 shares of common stock to eight new employees under the Company's 2023 Inducement Plan. The stock options will vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of the vesting commencement date and 1/48th of the underlying shares vesting monthly thereafter over 36 months, subject to the employee's continued service relationship with Syndax through the applicable vesting dates. About
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Syndax Pharmaceuticals Inc.SCHEDULE 13G/A - Syndax Pharmaceuticals Inc (0001395937) (Subject)
- PRSyndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)NEW YORK, March 04, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (NASDAQ:SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that on March 1, 2026, the Company granted inducement awards to purchase up to 81,600 shares of common stock to three new employees under the Company's 2023 Inducement Plan. The stock options will vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of the vesting commencement date and 1/48th of the underlying shares vesting monthly thereafter over 36 months, subject to the employee's continued service relationship with Syndax through the applicable vesting dates. About
- SECSEC Form S-8 filed by Syndax Pharmaceuticals Inc.S-8 - Syndax Pharmaceuticals Inc (0001395937) (Filer)
- SECSEC Form 10-K filed by Syndax Pharmaceuticals Inc.10-K - Syndax Pharmaceuticals Inc (0001395937) (Filer)
- SECSyndax Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Syndax Pharmaceuticals Inc (0001395937) (Filer)
- PRSyndax Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update– Total revenue of $68.7 million in 4Q25 and $172.4 million in FY2025 – – Revuforj® (revumenib) net revenue of $44.2 million in 4Q25, a 38% increase vs 3Q25, and $124.8 million in FY2025 – – Niktimvo™ (axatilimab-csfr) net revenue of $56.0 million in 4Q25, a 22% increase vs 3Q25, and $151.6 million in FY2025, resulting in Syndax collaboration revenue of $42.4 million in FY2025 – – Completed enrollment in Phase 2 IPF trial of axatilimab; topline data expected in 4Q26 – – Company to host a conference call today at 4:30 p.m. ET – NEW YORK, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (NASDAQ:SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer ther
SNDX FAQ
7 questionsWhat does Syndax Pharmaceuticals Inc. do?
Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 protein for the treatment of MLL-rearranged (MLLr) and nucleophosmin 1 mutant acute myeloid leukemia (NPM1c AML); and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD). The company is...Where does SNDX stock trade?
Syndax Pharmaceuticals Inc. (SNDX) is listed on NASDAQ.What sector and industry is SNDX in?
Syndax Pharmaceuticals Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Syndax Pharmaceuticals Inc. go public?
Syndax Pharmaceuticals Inc. (SNDX) completed its IPO in 2016.What are analysts saying about SNDX?
Syndax Pharmaceuticals Inc. has had 8 recent analyst actions on file. The most recent action was from H.C. Wainwright: Buy with a $4000.00 price target on 2025-10-16. Recent price targets range from $1800.00 to $4400.00.What companies are similar to SNDX?
Notable peers in the same industry include LLY (Eli Lilly and Company), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare SNDX side-by-side with any of them on Quantisnow.How can I track SNDX on Quantisnow?
Quantisnow aggregates Syndax Pharmaceuticals Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow SNDX to receive live email and push alerts on every new disclosure.